Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after aim lamivudine retreatment
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, So Young | - |
dc.contributor.author | Choe, Won Hyeok | - |
dc.contributor.author | Lee, Chang Hong | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.date.accessioned | 2021-09-09T05:56:36Z | - |
dc.date.available | 2021-09-09T05:56:36Z | - |
dc.date.created | 2021-06-10 | - |
dc.date.issued | 2008-07-21 | - |
dc.identifier.issn | 1007-9327 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/123016 | - |
dc.description.abstract | Lamivudine has a high rate of antiviral resistance. Sequential treatment of anti-hepatitis B virus (HBV) Is commonly used for lamivudine resistance. We report 4 cases of patients with rapid redetection of HBV mutants during the lamivudine retreatment. The four patients received lamivudine as an initial treatment of HBV and adefovir and lamivudine as a rescue therapy consecutively. HBV-DNA level, YMDD mutations and adefovir -resistant mutations (RFMP) were tested every 3 mo during the sequential treatment. All the patients showed YMDD mutations during the initial lamivudine therapy. After adefovir therapy for lamivudine resistance, they showed viral breakthrough. Adefovir was switched to lamivudine, however, it did not induce viral suppression at all, rather increased HBV-DNA with rapid reemergence of the YMDD mutations. All the patients had ALT flares, and hepatic decompensation occurred in two patients. After switching to adefovir combined with entecavir or lamivudine for a rescue therapy, the patients had reduction in HBV-DNA and ALT improvement. These cases demonstrated that lamivudine retreatment of patients with preexposed lamivudine resistance leads to rapid reemergence of YMDD mutation with significant viral rebounds and subsequent hepatic decompensation. Sequential administration of lamivudine in patients with a prior history of YMDD mutation should be abandoned. (c) 2008 The WJG Press. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | BAISHIDENG PUBLISHING GROUP INC | - |
dc.subject | ADEFOVIR DIPIVOXIL | - |
dc.subject | RESISTANT | - |
dc.subject | THERAPY | - |
dc.subject | COMBINATION | - |
dc.subject | INFECTION | - |
dc.title | Rapid re-emergence of YMDD mutation of hepatitis B virus with hepatic decompensation after aim lamivudine retreatment | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Yeon, Jong Eun | - |
dc.contributor.affiliatedAuthor | Byun, Kwan Soo | - |
dc.identifier.doi | 10.3748/wjg.14.4416 | - |
dc.identifier.scopusid | 2-s2.0-55949099628 | - |
dc.identifier.wosid | 000258148200027 | - |
dc.identifier.bibliographicCitation | WORLD JOURNAL OF GASTROENTEROLOGY, v.14, no.27, pp.4416 - 4419 | - |
dc.relation.isPartOf | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.title | WORLD JOURNAL OF GASTROENTEROLOGY | - |
dc.citation.volume | 14 | - |
dc.citation.number | 27 | - |
dc.citation.startPage | 4416 | - |
dc.citation.endPage | 4419 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | ADEFOVIR DIPIVOXIL | - |
dc.subject.keywordPlus | RESISTANT | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | INFECTION | - |
dc.subject.keywordAuthor | hepatitis B | - |
dc.subject.keywordAuthor | lamivudine | - |
dc.subject.keywordAuthor | adefovir dipivoxil | - |
dc.subject.keywordAuthor | mutations | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.